Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling is involved in the growth of normal and cancer cells and is crucial for T cell activation. Previously, we have shown that AKT Inhibitor VIII, a selective AKT-1/2 inhibitor, during chimeric antigen receptor (CAR) T cell manufacturi...
Saved in:
Main Authors: | Hui-Ju Hsieh, Ryan Urak, Mary C. Clark, Larry W. Kwak, Stephen J. Forman, Xiuli Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050125000166 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
by: Alice Sýkorová, et al.
Published: (2024-09-01) -
Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01) -
Primary extranodal NK/T cell lymphoma of stomach: A case report and review of literature
by: Prashant Mane, et al.
Published: (2024-04-01) -
PTEN suppresses renal cell carcinoma proliferation and migration via inhibition of the PI3K/AKT pathway
by: Xu Xu, et al.
Published: (2025-02-01) -
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01)